Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone
Status:
Completed
Trial end date:
2018-01-12
Target enrollment:
Participant gender:
Summary
Major depressive disorder (MDD) is highly prevalent and nearly 70% of individuals with MDD do
not respond to standard antidepressant therapies despite adequate dosing. An effective and
well-tolerated antidepressant augmentation therapy would have important clinical and public
health implications. Neuroactive steroid hormones are known to directly activate
neurotransmitter receptors in the brain, and thus are potential candidates for augmentation
therapies to enhance the effect of traditional antidepressants. The investigators hypothesize
that administration of an allopregnanolone analog in women with treatment-resistant
depression will improve depressive symptoms.